Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Pharma company announces manuscript publication for anticancer drug
December 28th, 2004
Maxim Pharmaceuticals (Nasdaq:MAXM)(SSE:MAXM) announced the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics describing Maxim's MX116407 anticancer drug candidate as part of a novel class of microtubule inhibitors with vascular targeting activity. The manuscripts characterize MX116407 as a potent caspase activator with strong antitumor activity in preclinical in vitro and in vivo studies. MX116407 appeared highly effective in mouse tumor models, producing tumor necrosis at doses that correspond to only 25% of the maximum tolerated dose. Moreover, in combination treatment, MX116407 significantly enhanced the...
Source: Cancer Weekly (2004-12-28)
|
